Select patients for treatment of unresectable or metastatic colorectal cancer with TUKYSA based on the presence of:
Metastatic Breast Cancer
The recommended dosage of TUKYSA is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity [see Clinical Studies (14.1)].
Unresectable or Metastatic Colorectal Cancer
The recommended dosage of TUKYSA is 300 mg taken orally twice daily in combination with trastuzumab until disease progression or unacceptable toxicity [see Clinical Studies (14.2)].
Advise patients to swallow TUKYSA tablets whole and not to chew, crush, or split prior to swallowing. Advise patients not to ingest tablet if it is broken, cracked, or not otherwise intact.
Advise patients to take TUKYSA approximately 12 hours apart and at the same time each day with or without a meal.
If the patient vomits or misses a dose of TUKYSA, instruct the patient to take the next dose at its usual scheduled time.
When given in combination with TUKYSA, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after a meal. TUKYSA and capecitabine can be taken at the same time. Refer to the Full Prescribing Information for trastuzumab and capecitabine for additional information.
The recommended TUKYSA dose reductions and dosage modifications for adverse reactions are provided in Tables 1 and 2. Refer to the Full Prescribing Information for trastuzumab and capecitabine for information about dosage modifications for these drugs.
| Dose Reduction | Recommended TUKYSA Dosage |
| First | 250 mg orally twice daily |
| Second | 200 mg orally twice daily |
| Third | 150 mg orally twice daily |
Permanently discontinue TUKYSA in patients unable to tolerate 150 mg orally twice daily.
| 1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 2. Abbreviations: ULN = upper limit of normal; ALT = alanine aminotransferase; AST = aspartate aminotransferase | ||
| Adverse Reaction1 | Severity | TUKYSA Dosage Modification |
| Diarrhea [see Warnings and Precautions (5.1)] | Grade 3 without anti-diarrheal treatment | Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level. |
| Grade 3 with anti-diarrheal treatment | Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. | |
| Grade 4 | Permanently discontinue TUKYSA. | |
| Hepatotoxicity2 [see Warnings and Precautions (5.2)] | Grade 2 bilirubin (>1.5 to 3 × ULN) | Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level. |
| Grade 3 ALT or AST (> 5 to 20 × ULN) OR Grade 3 bilirubin (> 3 to 10 × ULN) | Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. | |
| Grade 4 ALT or AST (> 20 × ULN) OR Grade 4 bilirubin (> 10 × ULN) | Permanently discontinue TUKYSA. | |
| ALT or AST > 3 × ULN AND Bilirubin > 2 × ULN | Permanently discontinue TUKYSA. | |
| Other adverse reactions [see Adverse Reactions (6.1)] | Grade 3 | Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. |
| Grade 4 | Permanently discontinue TUKYSA. | |
For patients with severe hepatic impairment (Child-Pugh C), reduce the recommended dosage to 200 mg orally twice daily [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
Avoid concomitant use of strong CYP2C8 inhibitors with TUKYSA. If concomitant use with a strong CYP2C8 inhibitor cannot be avoided, reduce the recommended dosage to 100 mg orally twice daily. After discontinuation of the strong CYP2C8 inhibitor for 3 elimination half-lives, resume the TUKYSA dose that was taken prior to initiating the inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
Select patients for treatment of unresectable or metastatic colorectal cancer with TUKYSA based on the presence of:
Metastatic Breast Cancer
The recommended dosage of TUKYSA is 300 mg taken orally twice daily in combination with trastuzumab and capecitabine until disease progression or unacceptable toxicity [see Clinical Studies (14.1)].
Unresectable or Metastatic Colorectal Cancer
The recommended dosage of TUKYSA is 300 mg taken orally twice daily in combination with trastuzumab until disease progression or unacceptable toxicity [see Clinical Studies (14.2)].
Advise patients to swallow TUKYSA tablets whole and not to chew, crush, or split prior to swallowing. Advise patients not to ingest tablet if it is broken, cracked, or not otherwise intact.
Advise patients to take TUKYSA approximately 12 hours apart and at the same time each day with or without a meal.
If the patient vomits or misses a dose of TUKYSA, instruct the patient to take the next dose at its usual scheduled time.
When given in combination with TUKYSA, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes after a meal. TUKYSA and capecitabine can be taken at the same time. Refer to the Full Prescribing Information for trastuzumab and capecitabine for additional information.
The recommended TUKYSA dose reductions and dosage modifications for adverse reactions are provided in Tables 1 and 2. Refer to the Full Prescribing Information for trastuzumab and capecitabine for information about dosage modifications for these drugs.
| Dose Reduction | Recommended TUKYSA Dosage |
| First | 250 mg orally twice daily |
| Second | 200 mg orally twice daily |
| Third | 150 mg orally twice daily |
Permanently discontinue TUKYSA in patients unable to tolerate 150 mg orally twice daily.
| 1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 2. Abbreviations: ULN = upper limit of normal; ALT = alanine aminotransferase; AST = aspartate aminotransferase | ||
| Adverse Reaction1 | Severity | TUKYSA Dosage Modification |
| Diarrhea [see Warnings and Precautions (5.1)] | Grade 3 without anti-diarrheal treatment | Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level. |
| Grade 3 with anti-diarrheal treatment | Initiate or intensify appropriate medical therapy. Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. | |
| Grade 4 | Permanently discontinue TUKYSA. | |
| Hepatotoxicity2 [see Warnings and Precautions (5.2)] | Grade 2 bilirubin (>1.5 to 3 × ULN) | Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the same dose level. |
| Grade 3 ALT or AST (> 5 to 20 × ULN) OR Grade 3 bilirubin (> 3 to 10 × ULN) | Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. | |
| Grade 4 ALT or AST (> 20 × ULN) OR Grade 4 bilirubin (> 10 × ULN) | Permanently discontinue TUKYSA. | |
| ALT or AST > 3 × ULN AND Bilirubin > 2 × ULN | Permanently discontinue TUKYSA. | |
| Other adverse reactions [see Adverse Reactions (6.1)] | Grade 3 | Hold TUKYSA until recovery to ≤ Grade 1, then resume TUKYSA at the next lower dose level. |
| Grade 4 | Permanently discontinue TUKYSA. | |
For patients with severe hepatic impairment (Child-Pugh C), reduce the recommended dosage to 200 mg orally twice daily [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)].
Avoid concomitant use of strong CYP2C8 inhibitors with TUKYSA. If concomitant use with a strong CYP2C8 inhibitor cannot be avoided, reduce the recommended dosage to 100 mg orally twice daily. After discontinuation of the strong CYP2C8 inhibitor for 3 elimination half-lives, resume the TUKYSA dose that was taken prior to initiating the inhibitor [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.